Trending...
- Zero Foodprint's Holiday Gift Guide Turns Gifting into Giving!
- Los Defensores Joins ABC13's Share Your Holidays Food Drive to Support Houston Families
- The World's No.1 Superstar Is Celebrating His 21st Birthday for the 28th Time Today!
JUPITER, Fla. - CuisineWire -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum are among the first physicians in the country to administer the newly FDA-approved drug Kisunla to patients. This groundbreaking development marks a significant milestone in neurological care, offering new hope to patients battling a range of neurological conditions.
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on Cuisine Wire
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on Cuisine Wire
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on Cuisine Wire
- Shape the Future of OpenSSL: Election Period Open Now!
- LIB Empowers Uzbekistan's Automotive Industry: A New Era of Quality Assurance
- TijaraIQ.com Launches as Iraq's Free Marketplace for Buying, Selling, and Creating Opportunities
- Big News!! Best Sac Homes Group Partners with LPT Realty
- Bloom Bar Atlanta Hosts Holiday Food Drive to Support Neighbors in Need
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on Cuisine Wire
- Juventix Regenerative Medical PRP Highlighted in University-Published Research Study
- Dale Sorensen Real Estate Names Donna Browning Vice President of Sales, Announcing Her Return to the Company
- Dr. Barrie Matthews of Big Sky Smile Center Speaks at the Full Arch Growth Conference, Inspiring Dentists Nationwide
- Dr. Sathish Palayam Speaks at the Full Arch Growth Conference, Sharing Insights to Revolutionize Patient Care!
- Mr. Mac's Donates to Local Children's Programs
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Source: First Choice Neurology
0 Comments
Latest on Cuisine Wire
- Mrs Elemental® USA Rebrands to Empower Married Women Across the Nation
- Zero Foodprint's Holiday Gift Guide Turns Gifting into Giving!
- Los Defensores Joins ABC13's Share Your Holidays Food Drive to Support Houston Families
- Time to Investigate Mental Health Research Waste on Bizarre Animal Studies
- The World's No.1 Superstar Is Celebrating His 21st Birthday for the 28th Time Today!
- Who is Stan Fitzgerald Georgia Veterans for America First state chapter Political Director
- 4th Annual Pompano Fall Festival: Shirley Murdock, Adina Howard, Jeezy, and Plies Headline Broward County's Top Music Festival
- San Francisco Bay Area Songwriting Duo Razteria and Dave Shul Release Retro Rock Pop Album Prowess Blossoming
- Best Romantic Holidays to Ring in the New Year in İstanbul!
- Le trio français de Punk-Metal Psychédélique Joe La Truite signe un contrat de management international
- Help Disabled American Homeless Veteran Become Financially Independent
- Ultimate Spades Tour Launches Groundbreaking Series From Creators Mekhi Phifer And Lawrence Adisa On Thanksgiving 2024
- Jones Sign Unveils Jones Vision LED Displays
- BWoo Foods Announces Rapid Growth and Expansion
- Cryptsoft Pty Ltd. has added support for CockroachDB in the latest release of KMIP Server SDKs
- Naturally New York Announces Inaugural Holiday Bazaar Event, Presented by Bank of America
- See Our Earth Inspires Adventure and Conservation with Mountain Hats and Dad Caps
- National Survey Reveals 2 in 5 Employed Americans Think Their Benefits Will Be Impacted by the New Administration
- Kids and Culture, LLC Recognized as a Top 100 MBE®
- Compliant Workspace Expands Microsoft 365 Data Backup Service to Empower Small Businesses on the Cloud